EVALUATING THE IMPACT OF FGL2-MEDIATED IMMUNE RESPONSES ON LIVER HEALTH AND PERFORMANCE IN ATHLETES WITH HBV-ACLF

Abstract

Objective: This study aims to explore the role of FGL2-mediated immune coagulation in liver injury among athletes suffering from hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF), examining how this could impact athletic performance and recovery. Methods: A cohort of 66 HBV-ACLF patients, including athletes, was studied at the Ninth Hospital of Nanchang from 2019 to 2020. Patients were divided into two subgroups: 31 in the experimental group (A-ACLF) and 35 in the control group (P-ACLF). Serum levels of PAR1, C5b9, TNF-α, and FGL2 were measured using ELISA to assess immune coagulation. Results: The study predominantly included male patients, with those in the A-ACLF subgroup having an average age of 47 years and a hospital stay of 39 days, while those in the P-ACLF subgroup averaged 40 years of age with a 61-day hospital stay. Significant differences in serum levels of PAR1, C5b9, TNF-α, and FGL2 were observed between the groups, indicating the potential impact of these factors on liver health and recovery dynamics in HBV-ACLF patients, including athletes. Conclusion: FGL2-mediated immunocoagulation significantly influences the progression and prognosis of HBV-ACLF, affecting liver function which is crucial for athletic performance. The results suggest that monitoring these immune coagulation markers can provide valuable insights into the health status and recovery prospects of athletes with HBV-ACLF, offering a new perspective for clinical evaluation and management strategies tailored to this population.